fbpx

Recent Patent Oppositions in the Pharmaceutical Industry

Oppositions in Pharma Notable Recent Patent Oppositions in the Industry

Table of Contents

The European Patent Office (EPO) receives more than 2000 oppositions each year, directly impacting the future success and exclusivity of pharmaceutical products.

Monitoring the outcomes of these oppositions is crucial as it assists in developing effective strategies for launching generic versions of drugs. Moreover, it aids in identifying competitors that may be eating into market share. 

Like every year, the pharmaceutical sector has seen high opposition filings this year as well.

Patent Opposition Trends in Pharmaceutical Industry

One patent that has attracted significant attention is from Novartis.

Novartis’ patent EP2959894B1 and Biogen’s patent EP2653873B8, focusing on multiple sclerosis (MS) treatment, have faced over 23 and 14 oppositions, respectively. This highlights the importance of S1P receptor modulators and positions Novartis & Biogen as a key player in advancing MS therapies. Similarly, Novo Nordisk’s patent EP3448416A1 for Semaglutide, a treatment for type 2 diabetes, encountered substantial opposition but still managed to secure a notable position in the rankings.

Author’s note – As top blockbuster drugs approach patent expiration, strategic ANDA filings are critical to secure early mover advantage. Download the Pharsight Digester report now for a deep dive into the patent strategies of the top 5 blockbuster drugs nearing expiration.

Top Patents Facing Opposition

Below is a curated list of the top patents facing multiple oppositions, offering insights into the intricate web of pharmaceutical advancements.

Patent NumberTitleAssigneeNo. of opponents
EP2959894B1S1P receptor modulators for treating multiple sclerosisNovartis23
EP3294283B1Sacubitril-valsartan dosage regimen for treating heart failureNovartis15
EP2653873B8Compositions and uses for treating multiple sclerosisBiogen14
EP3590949B1Ribonucleic acids containing n1-methyl-pseudouracils and uses thereofModerna9
EP2981255B1Therapeutic uses of empagliflozinBoehringer Ingelheim10
EP3597659B1Prevention of disulfide bond reduction during recombinant production of polypeptidesGenentech
9
EP3524595B1High-purity quinoline derivative and method for manufacturing the sameEisai9
EP3448416B1Semaglutide in cardiovascular conditionsNovo Nordisk8
EP3578175B1Rapid dissolution formulation of a calcium receptor-active compoundAmgen7
EP3324937B1Ready-to-use solution of bortezomibStada7
EP3324936B1Process for the preparation of a bortezomib ester solutionStada6
EP3067043B1Pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitorNovartis6
EP2397142B1Use of DPP IV inhibitorsBoehringer Ingelheim5
EP3981427B9Pegylated liposomes for delivery of immunogen-encoding rnaGlaxoSmithKline5
EP2611467B1Small liposomes for delivery of immunogen-encoding rnaGlaxoSmithKline5

This compiled list provides insights into the patent oppositions across diverse pharmaceutical fields, ranging from neurological disorders to diabetes and high-purity quinoline derivatives to ribonucleic acids. 

Each entry in the list underscores the commitment of companies to safeguard their intellectual property rights while challenging others, highlighting the strategic significance of these patents in shaping the future of medicine.

Major pharmaceutical companies filing patent opposition

After reviewing contested patents, let’s look at the major corporations fighting over them. These companies, not just focused on drug development, actively shape innovation by contesting these patents.

Company NameTotal oppositions filed after 2023
Generics26
Sandoz22
Teva Pharmaceutical Industries15
Stada Arzneimittel12
Sanofi12
Edwards Lifesciences6
Pfizer6
DR Schn6
Biontech6
Synthon5
Salts Healthcare5

Generics has filed the maximum number of oppositions in the pharmaceutical industry, totaling 26. By doing so, they’re strategically working to maintain a competitive edge. This further allows them to capitalize on emerging innovations, fostering business growth and maintaining a competitive edge in the pharmaceutical industry.

Monitoring Patent Oppositions with Elixir 

While monitoring opposition is the answer to your problems, it can be a cumbersome task if done manually.

That is where Elixir can help!

Elixir is a patent monitoring platform that provides comprehensive insights into patent filings, oppositions, and related activities in the pharmaceutical domain.

With Elixir, you can efficiently track oppositions filed globally, ensuring you don’t miss any critical developments.

Source – Elixir

Customizable alert systems in Elixir allow users to receive notifications tailored to their interests or technology areas. This ensures timely updates on oppositions against their patents or competitors’.

By utilizing Elixir, you can proactively plan your strategies, stay ahead of competitors, and maximize the success of your products.

Don’t wait; book a demo today to experience Elixir firsthand!

Authored By – Sujeet Singh, Product Development

Edited By – Ridhima Mahajan, Marketing

Share This Article:

Meet The Authors

Related Articles

More Curated Insights For You

Facing A Roadblock On Your Project?

Our Experts Are Here To Help.